{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:36:10Z","timestamp":1788809770998,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t T\u00fcbingen, Junior Clinician Scientist Program"},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Preoperative chemoradiotherapy combined with total mesorectal excision (TME) is a\u00a0standard treatment for locally advanced rectal cancer (LARC). However, lateral pelvic lymph nodes (LPLNs) are often inadequately treated with standard regimens. This study examines the treatment and postoperative outcomes in LARC patients receiving a\u00a0simultaneous integrated boost (SIB) for LPLNs during long-course chemoradiotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included high-risk LARC patients (UICC, \u201cUnion Internationale Contre le Cancer\u201d,  stage\u00a0III) treated with preoperative chemoradiotherapy and SIB to LPLNs. Radiotherapy was delivered to the primary tumor and elective volumes with 50.4\u202fGy in 28\u00a0fractions, and an\u00a0SIB with a\u00a0median dose of 60.2\u202fGy was administered to clinically positive LPLNs. TME quality and postoperative complications were assessed using MERCURY and Clavien\u2013Dindo, respectively. Time-to-event data were analyzed according to Kaplan\u2013Meier.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between 2019 and 2023, 27\u00a0patients with high-risk LARC and LPLN metastases were treated with chemoradiotherapy. After a\u00a0median follow-up of 19\u00a0months, 2\u2011year overall survival was 80%, disease-free survival 80%, and local control of dose-escalated lymph nodes 100%. Three patients were managed nonoperatively after a\u00a0clinical complete response on endoscopy and imaging. Of the 22\u00a0patients who had surgery, only one had complications higher than Clavien\u2013Dindo\u00a0grade\u00a0I; TME was graded as MERCURY\u00a0I in 73%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion and conclusion<\/jats:title>\n            <jats:p>The SIB approach for LPLNs in LARC is feasible, does not increase postoperative morbidity, and achieves excellent local control. This study supports the consideration of dose-escalated radiotherapy for LPLNs to address high local recurrence risks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-024-02354-z","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T10:59:49Z","timestamp":1736852389000},"page":"706-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Simultaneous integrated boost to lateral pelvic lymph nodes during chemoradiotherapy in high-risk rectal cancer"],"prefix":"10.1007","volume":"201","author":[{"given":"Marcel","family":"B\u00fcttner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"B\u00f6ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"B\u00f6sm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f6rte","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0242-9428","authenticated-orcid":false,"given":"Cihan","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"9","key":"2354_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn\u00a0E et\u00a0al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N\u00a0Engl J Med 345(9):638\u2013646","journal-title":"N Engl J Med"},{"issue":"1","key":"2354_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1200\/JCO.18.00032","volume":"37","author":"A Ogura","year":"2019","unstructured":"Ogura\u00a0A et\u00a0al (2019) Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3\/4 Rectal Cancer. J\u00a0Clin Oncol 37(1):33\u201343","journal-title":"J Clin Oncol"},{"issue":"1","key":"2354_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/DCR.0000000000002936","volume":"67","author":"C Hassanzadeh","year":"2024","unstructured":"Hassanzadeh\u00a0C et\u00a0al (2024) Lateral Pelvic Nodal Management and Patterns of Failure in Patients Receiving Short-Course Radiation for Locally Advanced Rectal Cancer. Dis Colon Rectum 67(1):54\u201361","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"2354_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1055\/s-0037-1606109","volume":"30","author":"RJ Heald","year":"2017","unstructured":"Heald\u00a0RJ et\u00a0al (2017) The perfect total mesorectal excision obviates the need for anything else in the management of most rectal cancers. Clin Colon Rectal Surg 30(5):324\u2013332","journal-title":"Clin Colon Rectal Surg"},{"issue":"11","key":"2354_CR5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1470-2045(09)70224-4","volume":"10","author":"P Georgiou","year":"2009","unstructured":"Georgiou\u00a0P et\u00a0al (2009) Extended lymphadenectomy versus conventional surgery for rectal cancer: a\u00a0meta-analysis. Lancet Oncol 10(11):1053\u20131062","journal-title":"Lancet Oncol"},{"key":"2354_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fsurg.2019.00079","volume":"6","author":"J Otero de Pablos","year":"2019","unstructured":"Otero de Pablos\u00a0J, Mayol\u00a0J (2019) Controversies in the Management of Lateral Pelvic Lymph Nodes in Patients With Advanced Rectal Cancer: East or West? Front Surg 6:79","journal-title":"Front Surg"},{"key":"2354_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fsurg.2020.00041","volume":"7","author":"J Otero de Pablos","year":"2020","unstructured":"Otero de Pablos\u00a0J, Mayol Corrigendum\u00a0J (2020) Controversies in the Management of Lateral Pelvic Lymph Nodes in Patients With Advanced Rectal Cancer: East or West? Front Surg 7:41","journal-title":"Front Surg"},{"issue":"2","key":"2354_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clcc.2022.02.002","volume":"21","author":"TC Sluckin","year":"2022","unstructured":"Sluckin\u00a0TC et\u00a0al (2022) Lateral Lymph Nodes in Rectal Cancer: Do we all Think the Same? A\u00a0Review of Multidisciplinary Obstacles and Treatment Recommendations. Clin Colorectal Cancer 21(2):80\u201388","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"2354_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/codi.13966","volume":"20","author":"H Iversen","year":"2018","unstructured":"Iversen\u00a0H et\u00a0al (2018) Pelvic local recurrence from colorectal cancer: surgical challenge with changing preconditions. Colorectal Dis 20(5):399\u2013406","journal-title":"Colorectal Dis"},{"issue":"5","key":"2354_CR10","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1016\/j.prro.2019.12.007","volume":"10","author":"H Chen","year":"2020","unstructured":"Chen\u00a0H et\u00a0al (2020) Effect and Safety of Radiation Therapy Boost to Extramesorectal Lymph Nodes in Rectal Cancer. Pract Radiat Oncol 10(5):e372\u2013e377","journal-title":"Pract Radiat Oncol"},{"key":"2354_CR11","doi-asserted-by":"publisher","first-page":"627572","DOI":"10.3389\/fonc.2020.627572","volume":"10","author":"S Li","year":"2020","unstructured":"Li\u00a0S et\u00a0al (2020) Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy Can Benefit the Locally Advanced Rectal Cancer Patients With Clinically Positive Lateral Pelvic Lymph Node. Front Oncol 10:627572","journal-title":"Front Oncol"},{"issue":"3","key":"2354_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1245\/s10434-007-9696-x","volume":"15","author":"TH Kim","year":"2008","unstructured":"Kim\u00a0TH et\u00a0al (2008) Lateral lymph node metastasis is a\u00a0major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol 15(3):729\u2013737","journal-title":"Ann Surg Oncol"},{"key":"2354_CR13","doi-asserted-by":"crossref","unstructured":"Valentini V et\u00a0al International consensus guidelines on Clinical Target Volume delineation in rectal cancer. Radiother Oncol 2016:xxx","DOI":"10.1016\/j.radonc.2016.07.017"},{"issue":"7","key":"2354_CR14","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","volume":"13","author":"C R\u00f6del","year":"2012","unstructured":"R\u00f6del\u00a0C et\u00a0al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO\/ARO\/AIO-04 randomised phase\u00a03\u00a0trial. Lancet Oncol 13(7):679\u2013687","journal-title":"Lancet Oncol"},{"issue":"1","key":"2354_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","volume":"22","author":"RR Bahadoer","year":"2021","unstructured":"Bahadoer\u00a0RR et\u00a0al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a\u00a0randomised, open-label, phase\u00a03\u00a0trial. Lancet Oncol 22(1):29\u201342","journal-title":"Lancet Oncol"},{"issue":"5","key":"2354_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy\u00a0T et\u00a0al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a\u00a0multicentre, randomised, open-label, phase\u00a03\u00a0trial. Lancet Oncol 22(5):702\u2013715","journal-title":"Lancet Oncol"},{"issue":"7","key":"2354_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/2047-783X-15-7-292","volume":"15","author":"T Herzog","year":"2010","unstructured":"Herzog\u00a0T et\u00a0al (2010) TME quality in rectal cancer surgery. Eur J Med Res 15(7):292\u2013296","journal-title":"Eur J Med Res"},{"issue":"2","key":"2354_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien\u00a0PA et\u00a0al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187\u2013196","journal-title":"Ann Surg"},{"issue":"7","key":"2354_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s00066-023-02101-w","volume":"199","author":"E Riggenbach","year":"2023","unstructured":"Riggenbach\u00a0E, Lossl\u00a0K, Hemmatazad\u00a0H (2023) Dose escalation with brachytherapy to increase the organ preservation rate in rectal cancer. Strahlenther Onkol 199(7):694\u2013696","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"2354_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00066-022-01931-4","volume":"198","author":"M Fleischmann","year":"2022","unstructured":"Fleischmann\u00a0M et\u00a0al (2022) Image-guided high-dose-rate brachytherapy for rectal cancer: technical note and first clinical experience on an organ-preserving approach. Strahlenther Onkol 198(7):654\u2013662","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"2354_CR21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ijrobp.2023.10.009","volume":"118","author":"CA Fink","year":"2024","unstructured":"Fink\u00a0CA et\u00a0al (2024) Pelvic Irradiation for Node-Positive Prostate Cancer After Prostatectomy: Long-Term Results of the Prospective PLATIN\u20114 and PLATIN\u20115 Trials. Int J Radiat Oncol Biol Phys 118(4):1011\u20131017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2354_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S1470-2045(14)70205-0","volume":"15","author":"SY Jeong","year":"2014","unstructured":"Jeong\u00a0SY et\u00a0al (2014) Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 15(7):767\u2013774","journal-title":"Lancet Oncol"},{"issue":"11","key":"2354_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00384-018-3111-x","volume":"33","author":"H Aselmann","year":"2018","unstructured":"Aselmann\u00a0H et\u00a0al (2018) Robotic-assisted total mesorectal excision (TME) for rectal cancer results in a\u00a0significantly higher quality of TME specimen compared to the laparoscopic approach-report of a\u00a0single-center experience. Int J Colorectal Dis 33(11):1575\u20131581","journal-title":"Int J Colorectal Dis"},{"issue":"e181607","key":"2354_CR24","first-page":"8","volume":"153","author":"J Kitz","year":"2018","unstructured":"Kitz\u00a0J et\u00a0al (2018) Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO\/ARO\/AIO-04\u00a0Phase\u00a03 Randomized Clinical Trial. JAMA Surg 153(e181607):8","journal-title":"JAMA Surg"},{"issue":"4","key":"2354_CR25","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra\u00a0EA et\u00a0al (2023) Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: A\u00a05-Year follow-up of the RAPIDO trial. Ann Surg 278(4):e766\u2013e772","journal-title":"Ann Surg"},{"key":"2354_CR26","doi-asserted-by":"crossref","unstructured":"Meldolesi E et\u00a0al (2022) The Role of Simultaneous Integrated Boost in Locally Advanced Rectal Cancer Patients with Positive Lateral Pelvic Lymph Nodes. Cancers (basel) 14(7)","DOI":"10.3390\/cancers14071643"},{"issue":"6","key":"2354_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11864-016-0403-7","volume":"17","author":"S Balyasnikova","year":"2016","unstructured":"Balyasnikova\u00a0S, Brown\u00a0G (2016) Optimal Imaging Strategies for Rectal Cancer Staging and Ongoing Management. Curr Treat Options Oncol 17(6):32","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"2354_CR28","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1148\/radiol.2323031368","volume":"232","author":"S Bipat","year":"2004","unstructured":"Bipat\u00a0S et\u00a0al (2004) Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging\u2014a meta-analysis. Radiology 232(3):773\u2013783","journal-title":"Radiology"},{"issue":"1","key":"2354_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejrad.2003.12.005","volume":"52","author":"JH Kim","year":"2004","unstructured":"Kim\u00a0JH et\u00a0al (2004) High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol 52(1):78\u201383","journal-title":"Eur J Radiol"},{"key":"2354_CR30","first-page":"113","volume":"36","author":"PP Bulens","year":"2022","unstructured":"Bulens\u00a0PP et\u00a0al (2022) Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A\u00a0prospective cohort study. Clin Transl Radiat Oncol 36:113\u2013120","journal-title":"Clin Transl Radiat Oncol"},{"key":"2354_CR31","first-page":"153","volume":"37","author":"S Boeke","year":"2022","unstructured":"Boeke\u00a0S et\u00a0al (2022) Online MR guided dose escalated radiotherapy for organ preservation in distal rectal cancer. Clin Transl Radiat Oncol 37:153\u2013156","journal-title":"Clin Transl Radiat Oncol"},{"key":"2354_CR32","first-page":"100580","volume":"39","author":"J Steinke","year":"2023","unstructured":"Steinke\u00a0J et\u00a0al (2023) Planned organ preservation for elderly patients with rectal cancer using short course radiotherapy and a\u00a0contact brachytherapy boost\u2014an International multi-institution analysis. Clin Transl Radiat Oncol 39:100580","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02354-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02354-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02354-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T09:05:56Z","timestamp":1750410356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02354-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2354"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02354-z","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0B\u00fcttner, S.\u00a0Baumeister, R.\u00a0Bachmann, M.\u00a0Bitzer, H.\u00a0B\u00f6sm\u00fcller, D.\u00a0Wichmann, M.\u00a0Niyazi, and C.\u00a0Gani declare that they have no competing interests. The Department of Radiation Oncology receives technical and financial support from Elekta outside the current study. Honoraria: C.\u00a0Gani (Elekta). Travel expenses: C.\u00a0Gani, S.\u00a0B\u00f6ke, (Elekta).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}